CancerDrs

Cervical Cancer clinical trials in Texas

100 actively recruiting cervical cancer trials at 25 sites across Texas.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 3 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll.

Phase 3 Recruiting NIH

Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer

This phase III trial compares the addition of induction chemotherapy, with carboplatin, paclitaxel and pembrolizumab, to chemotherapy and radiation, with cisplatin and pembrolizumab followed by pembrolizumab maintenance for the treatment o…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT07061977
Sites in Texas:
  • Parkland Memorial Hospital — Dallas, Texas
  • UT Southwestern/Simmons Cancer Center-Dallas — Dallas, Texas
  • UT Southwestern/Simmons Cancer Center-Fort Worth — Fort Worth, Texas
  • UT Southwestern Clinical Center at Richardson/Plano — Richardson, Texas
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Academic/Other

Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer

This phase II/III trial studies how well sentinel lymph node biopsy works and compares sentinel lymph node biopsy surgery to standard neck dissection as part of the treatment for early-stage oral cavity cancer. Sentinel lymph node biopsy s…

Sponsor: NRG Oncology
NCT ID: NCT04333537
Sites in Texas:
  • MD Anderson in The Woodlands — Conroe, Texas
  • Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center — Houston, Texas
  • Michael E DeBakey VA Medical Center — Houston, Texas
  • UT MD Anderson Cancer Center — Houston, Texas
  • MD Anderson West Houston — Houston, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2)

This is a phase 3 open-label, randomized, controlled, multicenter study to compare petosemtamab vs investigator's choice monotherapy in HNSCC patients for the second- and third-line treatment of incurable metastatic/recurrent disease.

Sponsor: Merus B.V.
NCT ID: NCT06496178
Sites in Texas:
  • Site 55 — Denison, Texas
  • Site 34 — El Paso, Texas
  • Site 51 — Houston, Texas
  • Site 7 — Houston, Texas
  • Site 94 — Pearland, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)

This is a phase III, randomized, double-blind, placebo-controlled, multi-center, global study to explore the efficacy and safety of volrustomig in women with high-risk LACC (FIGO 2018 stage IIIA to IVA cervical cancer) who have not progres…

Sponsor: AstraZeneca
NCT ID: NCT06079671
Sites in Texas:
  • Research Site — Dallas, Texas
  • Research Site — Fort Worth, Texas
  • Research Site — Houston, Texas
  • Research Site — Tyler, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma

The purpose of this study is to compare the efficacy and safety of ficlatuzumab plus cetuximab compared to placebo plus cetuximab in participants with recurrent/metastatic (R/M) HPV-negative Head and Neck Cancer. The primary hypothesis is …

Sponsor: AVEO Pharmaceuticals, Inc.
NCT ID: NCT06064877
Sites in Texas:
  • MD Anderson Cancer Center — Houston, Texas
  • Oncology Consultants — Houston, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

SPECT-CT Guided ELEctive Contralateral Neck Treatment for Patients With Lateralized Oropharyngeal Cancer

This study is being done to answer the following question: Is the chance of cancer spreading or returning the same if radiotherapy to the neck is guided, by using a special imaging study called lymph node mapping (lymphatic mapping) Single…

Sponsor: Canadian Cancer Trials Group
NCT ID: NCT05451004
Sites in Texas:
  • UT MD Anderson - The Woodlands — Conroe, Texas
  • UT MD Anderson Cancer Center — Houston, Texas
  • UT MD Anderson - West Houston — Houston, Texas
  • UT MD Anderson - League City — League City, Texas
  • UT MD Anderson - Sugar Land — Sugar Land, Texas
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Industry

A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1

An open-label, controlled, multi-site, interventional, 2-arm, Phase II/III trial of BNT113 in combination with pembrolizumab vs pembrolizumab monotherapy as first line treatment in patients with unresectable recurrent or metastatic HPV16+ …

Sponsor: BioNTech SE
NCT ID: NCT04534205
Sites in Texas:
  • MD Anderson Cancer Center — Houston, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)

Researchers are looking for new ways to treat metastatic cervical cancer. Cervical cancer is cancer in the cervix, the lower part of the uterus (womb). Metastatic means the cancer has spread to other parts of the body. Researchers want to …

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT07216703
Sites in Texas:
  • Texas Oncology - DFW ( Site 8005) — Fort Worth, Texas
  • Texas Oncology-The Woodlands ( Site 8000) — The Woodlands, Texas
  • Texas Oncology - Northeast Texas ( Site 8002) — Tyler, Texas
View on ClinicalTrials.gov →
Phase 2 Recruiting Network

Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery

This phase II trial studies how well radiation therapy with or without cisplatin works in treating patients with stage III-IVA squamous cell carcinoma of the head and neck who have undergone surgery. Radiation therapy uses high energy x-ra…

Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT02734537
Sites in Texas:
  • Saint Joseph Regional Cancer Center — Bryan, Texas
  • MD Anderson in The Woodlands — Conroe, Texas
  • Parkland Memorial Hospital — Dallas, Texas
  • UT Southwestern/Simmons Cancer Center-Dallas — Dallas, Texas
  • University of Texas Medical Branch — Galveston, Texas
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

This study is to evaluate the safety, tolerability, and PK profiles of Elironrasib and Daraxonrasib as monotherapies and combination therapy in patients with KRAS G12C-mutated solid tumors.

Sponsor: Revolution Medicines, Inc.
NCT ID: NCT06128551
Sites in Texas:
  • Mary Crowley Cancer Research — Dallas, Texas
  • MD Anderson — Houston, Texas
  • NEXT Dallas — Irving, Texas
  • NEXT Oncology San Antonio — San Antonio, Texas
  • START Texas — San Antonio, Texas
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)

This study, the first clinical trial of AVZO-1418, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and antitumor activity of AVZO-1418 when administered intravenously as a monotherapy…

Sponsor: Avenzo Therapeutics, Inc.
NCT ID: NCT07038343
Sites in Texas:
  • Avenzo Therapeutics Recruiting Site — Dallas, Texas
  • Avenzo Therapeutics Recruiting Site — Houston, Texas
  • Avenzo Therapeutics Recruiting Site — San Antonio, Texas
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

This is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent administered intravenously in participants with advanced solid tumors that are antigen-ri…

Sponsor: Marengo Therapeutics, Inc.
NCT ID: NCT05592626
Sites in Texas:
  • The University of Texas, MD Anderson Cancer Center — Houston, Texas
  • UT Health Mays Cancer Center — San Antonio, Texas
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)

This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXD) in the following tumor types: endometrial cancer (EC); head and neck squamous cell carcinoma (HNSCC); pancreatic ductal adenocarcinoma (PDAC); colore…

Sponsor: Daiichi Sankyo
NCT ID: NCT06330064
Sites in Texas:
  • Texas Oncology - West Texas — Amarillo, Texas
  • Texas Oncology, P.A. — Dallas, Texas
  • Texas Oncology Gulf Coast — Pearland, Texas
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

This is a Phase 1/2, open-label, multicenter study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of TER-2013 in patients with advanced solid tumors harboring AKT/PI3K/PTEN pathway alteratio…

Sponsor: Terremoto Biosciences Inc.
NCT ID: NCT07109726
Sites in Texas:
  • NEXT Oncology — Austin, Texas
  • MD Anderson Cancer Center — Houston, Texas
  • START Center for Cancer Research — San Antonio, Texas
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

This is a multicenter, open-label, Phase 1/2 study of orally administered VMD-928 monotherapy and in combination with pembrolizumab in adult subjects with advanced solid tumors or lymphoma that have progressed or are non responsive to avai…

Sponsor: VM Oncology, LLC
NCT ID: NCT03556228
Sites in Texas:
  • The University of Texas MD Anderson Cancer Center (site 127) — Houston, Texas
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

This is a proof-of-concept study designed to investigate HER3-DXd monotherapy in locally advanced unresectable or metastatic solid tumors. The study is enrolling cohorts of participants with melanoma \[cutaneous/acral\], squamous cell carc…

Sponsor: Daiichi Sankyo
NCT ID: NCT06172478
Sites in Texas:
  • The University of Texas MD Anderson Cancer Center — Houston, Texas
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

First in Human Study of TUB-030 in Patients With Advanced Solid Tumors

The goal of this clinical trial is to learn if the drug TUB-030 works to treat solid cancer in adults. The study will also explore the safety of TUB-030. The main questions it aims to answer are: To determine the safety and tolerability of…

Sponsor: Tubulis GmbH
NCT ID: NCT06657222
Sites in Texas:
  • NEXT Oncology Austin — Austin, Texas
  • NEXT Oncology - Dallas — Irving, Texas
  • NEXT Oncology - San Antonio — San Antonio, Texas
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors

The purpose of this study is to assess the safety, tolerability, and recommended dose(s) of BMS-986340 as monotherapy and in combination with nivolumab, docetaxel, or Pumitamig in participants with advanced solid tumors. This study is a fi…

Sponsor: Bristol-Myers Squibb
NCT ID: NCT04895709
Sites in Texas:
  • Houston Methodist Hospital — Houston, Texas
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

Researchers are looking for a better way to treat people who have solid tumors with HER2-activating mutations. Before a treatment can be approved for people to take, researchers do clinical trials to better understand its safety and how it…

Sponsor: Bayer
NCT ID: NCT06760819
Sites in Texas:
  • The University of Texas MD Anderson Cancer Center - Texas Medical Center — Houston, Texas
View on ClinicalTrials.gov →

Showing 25 of 100 trials with sites in Texas. See all cervical cancer trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-07-27